Adjuvant chemotherapy for rectal cancer

The Lancet Oncology

Volumn 15, Issue 6, 2014, Pages

  Atkins, Carl D ^a  

^a St Peter's Hospital Albany   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DRUG EFFECT; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; RECTUM CANCER; TREATMENT PLANNING; ABDOMINAL SURGERY; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; FEMALE; MALE; NOTE; RECTUM TUMOR;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; RECTAL NEOPLASMS;

EID: 84899739484     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70120-2     Document Type: Letter

References (4)

1. Bosset J-F, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014, 15:184-190.
2. Beets GL, Glimelius BL Adjuvant chemotherapy for rectal cancer still controversial. Lancet Oncol 2014, 15:130-131.
3. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
4. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999, 17:1356-1363. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2).